CTLA4 and Miyoshi myopathy: Nivolumab (a PD-1 checkpoint inhibitor) and ipilimumab (a CTLA-4 checkpoint inhibitor) have complementary activities in MM, compared with ipilimumab monotherapy, two-drug treatment significantly improved the PFS of patients (51, 52).